Moreover, our functional data underscore the value of SFTA1P as a candidate therapeutic target in NSCLC, given that the depletion of SFTA1P resulted in the activation of pro-apoptotic pathways and remarkably compromised tumor growth/induction in vitro and in vivo. This evidence concerns the gene SFTA1P and neoplasm.